BBP-812
- Generic Name
- BBP-812
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation
FDA grants RMAT designation to BridgeBio's BBP-812 gene therapy for Canavan disease, based on CANaspire trial data showing functional improvements in all dosed patients.
Related Clinical Trials:
BridgeBio Pharma Gets FDA Regenerative Medicine Advanced Therapy Designation
BridgeBio Pharma's Canavan disease treatment BBP-812 granted regenerative medicine advanced therapy designation by FDA, based on CANaspire Phase 1/2 clinical trial data. The treatment has also received orphan drug, rare pediatric disease, and fast track designations from the FDA and Orphan Drug Designation from the European Medicines Agency.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath